Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

Gebler, Christina; Lohoff, Tim; Paszkowski-Rogacz, Maciej; Mircetic, Jovan; Chakraborty, Debojyoti; Camgoz, Aylin; Hamann, Martin V; Theis, Mirko; Thiede, Christian; Buchholz, Frank

doi:10.1093/jnci/djw183

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Gebler, C., Lohoff, T., Paszkowski-Rogacz, M., Mircetic, J., Chakraborty, D., Camgoz, A., et al. (2017). Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. Journal of the National Cancer Institute, 109(1): djw183. doi:10.1093/jnci/djw183.

Cite as: https://hdl.handle.net/21.11116/0000-0002-8C39-1

Abstract

Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.